METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR EVENTS AND RELATED DISEASES USING SGLT-2 INHIBITORS
The present invention relates to the use of certain SGLT-2 inhibitors, such as ertugliflozin or a pharmaceutically acceptable salt or a co-crystal thereof, for treating, reducing the risk of and/or preventing heart failure, myocardial infarction, cardiovascular disease or cardiovascular death in animals without type 2 or type 1 diabetes mellitus, or in animals with pre-diabetes, or in animals with type 2 or type 1 diabetes mellitus or pre-diabetes.
1 - 33 . (canceled)
34 . A method of reducing the risk of cardiovascular disease in a human comprising administering ertugliflozin or a co-crystal thereof in a therapeutically effective amount to the human, wherein the human has type 2 or type 1 diabetes.
35 . The method of reducing the risk of cardiovascular disease in a human of claim 34 , wherein the human has type 2 diabetes.
36 . The method of reducing the risk of cardiovascular disease in a human of claim 34 , wherein the ertugliflozin or a pharmaceutically acceptable salt or a co-crystal thereof is administered as a pharmaceutical composition.
37 . The method of reducing the risk of cardiovascular disease in a human of claim 36 , wherein, the pharmaceutical composition comprises from 0.1 to 500 mg of ertugliflozin or a pharmaceutically acceptable salt or a co-crystal thereof.
38 . The method of reducing the risk of cardiovascular disease in a human of claim 36 , wherein, the pharmaceutical composition comprises from 1 to 200 mg.
39 . The method of reducing the risk of cardiovascular disease in a human of claim 36 , wherein, the pharmaceutical composition comprises from 2 to 100 mg.
40 . The method of reducing the risk of cardiovascular disease in a human of claim 36 , wherein, the pharmaceutical composition comprises from 2 to 20 mg of ertugliflozin or a pharmaceutically acceptable salt or a co-crystal thereof.
41 . The method of reducing the risk of cardiovascular disease in a human of claim 36 , wherein, the pharmaceutical composition comprises 5 mg of ertugliflozin or a pharmaceutically acceptable salt or a co-crystal thereof.
42 . The method of reducing the risk of cardiovascular disease in a human of claim 36 , wherein, the pharmaceutical composition comprises 5 mg of ertugliflozin or a pharmaceutically acceptable salt or a co-crystal thereof.
43 . The method of reducing the risk of cardiovascular disease in a human of claim 36 , wherein, the pharmaceutical composition is administered once daily.
44 . A method of reducing the risk of cardiovascular death in a human comprising administering ertugliflozin or a co-crystal thereof in a therapeutically effective amount to the human, wherein the human has type 2 or type 1 diabetes.
45 . The method of reducing the risk of cardiovascular death in a human of claim 44 , wherein the human has type 2 diabetes.
46 . The method of reducing the risk of cardiovascular death in a human of claim 44 , wherein the ertugliflozin or a pharmaceutically acceptable salt or a co-crystal thereof is administered as a pharmaceutical composition.
47 . The method of reducing the risk of cardiovascular death in a human of claim 46 , wherein, the pharmaceutical composition comprises from 0.1 to 500 mg of ertugliflozin or a pharmaceutically acceptable salt or a co-crystal thereof.
48 . The method of reducing the risk of cardiovascular death in a human of claim 46 , wherein, the pharmaceutical composition comprises from 1 to 200 mg.
49 . The method of reducing the risk of cardiovascular death in a human of claim 46 , wherein, the pharmaceutical composition comprises from 2 to 100 mg.
50 . The method of reducing the risk of cardiovascular death in a human of claim 46 , wherein, the pharmaceutical composition comprises from 2 to 20 mg of ertugliflozin or a pharmaceutically acceptable salt or a co-crystal thereof.
51 . The method of reducing the risk of cardiovascular death in a human of claim 46 , wherein, the pharmaceutical composition comprises 5 mg of ertugliflozin or a pharmaceutically acceptable salt or a co-crystal thereof.
52 . The method of reducing the risk of cardiovascular death in a human of claim 46 , wherein, the pharmaceutical composition comprises 5 mg of ertugliflozin or a pharmaceutically acceptable salt or a co-crystal thereof.
53 . The method of reducing the risk of cardiovascular death in a human of claim 46 , wherein, the pharmaceutical composition is administered once daily.